69 related articles for article (PubMed ID: 8854086)
1. An improved method for the detection of peptide-induced upregulation of HLA-A2 molecules on TAP-deficient T2 cells.
Regner M; Claësson MH; Bregenholt S; Röpke M
Exp Clin Immunogenet; 1996; 13(1):30-5. PubMed ID: 8854086
[TBL] [Abstract][Full Text] [Related]
2. Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells.
Smith KD; Lutz CT
J Immunol; 1996 May; 156(10):3755-64. PubMed ID: 8621911
[TBL] [Abstract][Full Text] [Related]
3. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
4. Carrier-mediated uptake and presentation of a major histocompatibility complex class I-restricted peptide.
Brander C; Wyss-Coray T; Mauri D; Bettens F; Pichler WJ
Eur J Immunol; 1993 Dec; 23(12):3217-23. PubMed ID: 8258336
[TBL] [Abstract][Full Text] [Related]
5. Major histocompatibility complex class I molecules interact with both subunits of the transporter associated with antigen processing, TAP1 and TAP2.
Powis SJ
Eur J Immunol; 1997 Oct; 27(10):2744-7. PubMed ID: 9368636
[TBL] [Abstract][Full Text] [Related]
6. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry.
Weinzierl AO; Rudolf D; Hillen N; Tenzer S; van Endert P; Schild H; Rammensee HG; Stevanović S
Eur J Immunol; 2008 Jun; 38(6):1503-10. PubMed ID: 18446792
[TBL] [Abstract][Full Text] [Related]
7. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2.
Guichard G; Connan F; Graff R; Ostankovitch M; Muller S; Guillet JG; Choppin J; Briand JP
J Med Chem; 1996 May; 39(10):2030-9. PubMed ID: 8642561
[TBL] [Abstract][Full Text] [Related]
8. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells.
Kobayashi H; Kimura S; Aoki N; Sato K; Celis E; Katagiri M
Immunogenetics; 2001 Oct; 53(8):626-33. PubMed ID: 11797095
[TBL] [Abstract][Full Text] [Related]
9. Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells.
Wang F; Li X; Annis B; Faustman DL
Hum Gene Ther; 1995 Aug; 6(8):1005-17. PubMed ID: 7578413
[TBL] [Abstract][Full Text] [Related]
10. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
11. The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics.
Grommé M; van der Valk R; Sliedregt K; Vernie L; Liskamp R; Hämmerling G; Koopmann JO; Momburg F; Neefjes J
Eur J Immunol; 1997 Apr; 27(4):898-904. PubMed ID: 9130642
[TBL] [Abstract][Full Text] [Related]
12. Peptide transporters and antigen processing.
Momburg F; Roelse J; Neefjes J; Hämmerling GJ
Behring Inst Mitt; 1994 Jul; (94):26-36. PubMed ID: 7998911
[TBL] [Abstract][Full Text] [Related]
13. Major histocompatibility complex class I-restricted alloreactive CD4+ T cells.
Boyle LH; Goodall JC; Gaston JS
Immunology; 2004 May; 112(1):54-63. PubMed ID: 15096184
[TBL] [Abstract][Full Text] [Related]
14. p53 induces TAP1 and enhances the transport of MHC class I peptides.
Zhu K; Wang J; Zhu J; Jiang J; Shou J; Chen X
Oncogene; 1999 Dec; 18(54):7740-7. PubMed ID: 10618714
[TBL] [Abstract][Full Text] [Related]
15. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay.
Stuber G; Leder GH; Storkus WT; Lotze MT; Modrow S; Székely L; Wolf H; Klein E; Kärre K; Klein G
Eur J Immunol; 1994 Mar; 24(3):765-8. PubMed ID: 8125143
[TBL] [Abstract][Full Text] [Related]
16. The effect of the proteasome inhibitor lactacystin on the presentation of transporter associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules.
Bai A; Forman J
J Immunol; 1997 Sep; 159(5):2139-46. PubMed ID: 9278300
[TBL] [Abstract][Full Text] [Related]
17. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences.
Neisig A; Roelse J; Sijts AJ; Ossendorp F; Feltkamp MC; Kast WM; Melief CJ; Neefjes JJ
J Immunol; 1995 Feb; 154(3):1273-9. PubMed ID: 7822796
[TBL] [Abstract][Full Text] [Related]
18. Translocation of long peptides by transporters associated with antigen processing (TAP).
Koopmann JO; Post M; Neefjes JJ; Hämmerling GJ; Momburg F
Eur J Immunol; 1996 Aug; 26(8):1720-8. PubMed ID: 8765012
[TBL] [Abstract][Full Text] [Related]
19. Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.
Seliger B; Höhne A; Knuth A; Bernhard H; Ehring B; Tampé R; Huber C
Clin Cancer Res; 1996 Aug; 2(8):1427-33. PubMed ID: 9816317
[TBL] [Abstract][Full Text] [Related]
20. MHC class I/beta 2-microglobulin complexes associate with TAP transporters before peptide binding.
Ortmann B; Androlewicz MJ; Cresswell P
Nature; 1994 Apr; 368(6474):864-7. PubMed ID: 8159247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
